Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
Hugh J McmillanCrystal M ProudMichelle A FarrarIan E AlexanderFrancesco MuntoniLaurent ServaisPublished in: Expert opinion on biological therapy (2022)
Onasemnogene abeparvovec has demonstrated efficacy in clinical trials and, because of this, is a valuable treatment option for patients with symptomatic infantile SMA and those identified by newborn screening. Gene therapy is still in its infancy, and challenges and uncertainties associated with transgene delivery must be addressed. With ongoing development of vector technology, more specific tissue tropism, reduced 'off-target' effects, and an enhanced safety profile will continue to evolve.